Joel B Epstein1,2, Judith E Raber-Durlacher3,4, Geena L Epstein5, Mette D Hazenberg6, Dimitrios Tzachanis7, Ricardo T Spielberger8. 1. City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. jepstein@coh.org. 2. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health Center, Los Angeles, CA, 90048, USA. jepstein@coh.org. 3. Department of Oral Medicine, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, Netherlands. 4. Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam, 1100 DD, Amsterdam, Netherlands. 5. , Beverly Hills, USA. 6. Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. 7. Moores Cancer Center, University of California, San Diego, CA, USA. 8. City of Hope Comprehensive Cancer Center/Kaiser Permanente, Duarte, CA, 91010, USA.
Abstract
This study presents follow-up of a prior study of patients with chronic symptomatic oral chronic graft-versus-host-disease (cGVHD) managed with photobiomodulation therapy (PBM therapy for 1 month. Here, we report long-term follow-up of a series of patients where PBM therapy in patients with oral cGVHD for maintenance follows the initial period of PBM therapy for continuing management. PATIENTS AND METHODS: We report continuing follow-up of 7 cases of oral cGVHD that were treated with PBM therapy. PBM therapy was continued in these patients with the goal of determining the best management schedule of PBM to maintain or improve control of each patient's symptoms and signs of oral cGVHD. RESULTS: Oral sensitivity and mucosal changes of cGVHD were controlled with a continuing schedule of PBM therapy of up to 6-8-week treatment intervals in patients with continuing GVHD. These findings suggest that PBM therapy represents an additional approach for continuing management of oral cGVHD and that the frequency of treatment should be individualized for each patient to provide best control of oral findings. In one case weekly PBM treatment was continued, while in others, management on a monthly or bimonthly basis was associated with control of the oral condition. PBM may be individualized and provided based upon best control of the symptoms and signs of oral GVHD.
This study presents follow-up of a prior study of patients with chronic symptomatic oral chronic graft-versus-host-disease (cGVHD) managed with photobiomodulation therapy (PBM therapy for 1 month. Here, we report long-term follow-up of a series of patients where PBM therapy in patients with oral cGVHD for maintenance follows the initial period of PBM therapy for continuing management. PATIENTS AND METHODS: We report continuing follow-up of 7 cases of oral cGVHD that were treated with PBM therapy. PBM therapy was continued in these patients with the goal of determining the best management schedule of PBM to maintain or improve control of each patient's symptoms and signs of oral cGVHD. RESULTS: Oral sensitivity and mucosal changes of cGVHD were controlled with a continuing schedule of PBM therapy of up to 6-8-week treatment intervals in patients with continuing GVHD. These findings suggest that PBM therapy represents an additional approach for continuing management of oral cGVHD and that the frequency of treatment should be individualized for each patient to provide best control of oral findings. In one case weekly PBM treatment was continued, while in others, management on a monthly or bimonthly basis was associated with control of the oral condition. PBM may be individualized and provided based upon best control of the symptoms and signs of oral GVHD.
Authors: Danica Vidović Juras; Josip Lukac; Ana Cekić-Arambasin; Andelko Vidović; Ivana Canjuga; Miroslav Sikora; Andreja Carek; Mario Ledinsky Journal: Coll Antropol Date: 2010-09